Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Disease Type
3.2. Market Snippet by Therapeutics
3.3. Market Snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Older Population
4.1.1.2. Increasing Prevalence of Bacterial Infectious Diseases
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. Adverse Effects of Therapeutics
4.1.2.2. Genetic Mutations
4.1.2.3. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
7.3. Market Attractiveness Index, By Disease Type Segment
7.3.1. Bacterial Skin Infections*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Foodborne Bacterial Infections
7.3.3. Sexually Transmitted Bacterial Infections
7.3.4. Others
8. By Therapeutics
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
8.3. Market Attractiveness Index, By Therapeutics Segment
8.3.1. Beta-Lactam*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Quinolones
8.3.3. Macrolides
8.3.4. Tetracyclines
8.3.5. Sulfonamide
8.3.6. Others
9. By Route of Administration
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.3. Market Attractiveness Index, By Route of Administration Segment
9.3.1. Oral*
9.3.1.1. Introduction
9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3.2. Topical
9.3.3. Parenteral
9.3.4. Others
10. By Distribution Channel
10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3. Market Attractiveness Index, By Distribution Channel Segment
10.3.1. Hospitals Pharmacies*
10.3.1.1. Introduction
10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
11. By Region
11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Novartis AG*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. GlaxoSmithkline plc
13.3. Pfizer Inc.
13.4. Merck & Co., Inc.
13.5. Sanofi
13.6. Allergan
13.7. Bayer AG
13.8. AstraZeneca Plc
13.9. Bristol-Myers Squibb Company
13.10. Takeda Pharmaceutical Company Limited
13.11. Baxter
13.12. Eli Lilly and Company
13.13. Johnson and Johnson
13.14. Insmed, Inc.
13.15. Otsuka Pharmaceuticals Co., Ltd.
13.16. Roche Holding AG
13.17. Forest Laboratories, Inc.
13.18. Teva Pharmaceuticals Industries Ltd. (LIST NOT EXHAUSTIVE)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us